Nuvectis Pharma, Inc. (NVCT)
Largest Insider Buys in Sector
NVCT Stock Price History Chart
NVCT Stock Performance
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Insider Activity of Nuvectis Pharma, Inc.
Over the last 12 months, insiders at Nuvectis Pharma, Inc. have bought $195,885 and sold $22,478 worth of Nuvectis Pharma, Inc. stock.
On average, over the past 5 years, insiders at Nuvectis Pharma, Inc. have bought $2.45M and sold $22,478 worth of stock each year.
Highest buying activity among insiders over the last 12 months: BENTSUR RON (Chairman & CEO) — $351,451. Poradosu Enrique (Chief Science & Business Off) — $13,125. Shemesh Shay (Chief Dev. & Ops. Officer) — $7,034.
The last purchase of 2,000 shares for transaction amount of $9,980 was made by Poradosu Enrique (Chief Science & Business Off) on 2024‑11‑19.
List of Insider Buy and Sell Transactions, Nuvectis Pharma, Inc.
| 2024-11-19 | Chief Science & Business Off | 2,000 0.0103% | $4.99 | $9,980 | +1.20% | |||
| 2024-11-15 | Chairman & CEO | 20,000 0.0887% | $4.92 | $98,400 | +0.71% | |||
| 2024-11-07 | Sale | Vice President, Finance | 2,755 0.0146% | $8.16 | $22,478 | +27.94% | ||
| 2024-05-14 | Chairman & CEO | 1,940 0.0105% | $6.74 | $13,076 | -2.00% | |||
| 2024-05-10 | Chairman & CEO | 2,000 0.0109% | $6.40 | $12,800 | +3.52% | |||
| 2024-05-10 | Chief Science & Business Off | 500 0.0027% | $6.29 | $3,145 | +3.52% | |||
| 2024-05-10 | Chief Dev. & Ops. Officer | 1,113 0.006% | $6.32 | $7,034 | +3.52% | |||
| 2024-03-18 | Chairman & CEO | 5,000 0.0283% | $10.29 | $51,450 | -35.79% | |||
| 2023-10-10 | Chairman & CEO | 640 0.0038% | $11.08 | $7,091 | -31.90% | |||
| 2023-10-09 | Chairman & CEO | 830 0.0049% | $11.19 | $9,288 | -32.61% | |||
| 2023-10-06 | Chairman & CEO | 250 0.0014% | $11.27 | $2,818 | -34.47% | |||
| 2023-10-05 | Chairman & CEO | 1,400 0.0076% | $11.09 | $15,526 | -31.83% | |||
| 2023-10-04 | Chairman & CEO | 1,820 0.0098% | $10.95 | $19,929 | -32.59% | |||
| 2023-08-16 | Chairman & CEO | 115 0.0008% | $15.15 | $1,742 | -42.41% | |||
| 2023-08-15 | Chairman & CEO | 235 0.0015% | $14.34 | $3,370 | -41.99% | |||
| 2023-08-11 | Chairman & CEO | 180 0.0011% | $14.66 | $2,639 | -46.24% | |||
| 2023-08-08 | Chairman & CEO | 120 0.0008% | $14.83 | $1,780 | -44.32% | |||
| 2023-07-31 | 10 percent owner | 860 0.0058% | $13.88 | $11,937 | -41.05% | |||
| 2023-07-28 | 10 percent owner | 2,584 0.0175% | $13.91 | $35,943 | -40.01% | |||
| 2023-07-27 | 10 percent owner | 1,556 0.0106% | $13.98 | $21,753 | -22.47% |
Insider Historical Profitability
| BENTSUR RON | Chairman & CEO | 3266424 16.9061% | $5.12 | 54 | 0 | +8.4% |
| Poradosu Enrique | Chief Science & Business Off | 1506319 7.7963% | $5.12 | 6 | 0 | +25.81% |
| Shemesh Shay | Chief Dev. & Ops. Officer | 1493068 7.7277% | $5.12 | 13 | 0 | +27.08% |
| Mosseri Marlio Charles | 10 percent owner | 2595000 13.431% | $5.12 | 19 | 0 | <0.0001% |
| Hoberman Kenneth | 55140 0.2854% | $5.12 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $3.06M | 2.03 | 372,721 | -3.91% | -$124,394.03 | <0.0001 | |
| The Vanguard Group | $2.45M | 1.63 | 298,800 | +1.53% | +$37,039.39 | <0.0001 | |
| Baldwin Brothers Inc Ma | $1.26M | 0.84 | 154,130 | +8.51% | +$99,138.00 | 0.1 | |
| Geode Capital Management | $1.1M | 0.73 | 134,528 | +2.18% | +$23,544.11 | <0.0001 | |
| State Street | $1.06M | 0.71 | 129,379 | +9.38% | +$91,020.02 | <0.0001 |